Federal Circuit says Pfizer arthritis drug was double patented

The US Court of Appeals for the Federal Circuit has affirmed a lower court ruling which said that a reissue patent covering Pfizer’s arthritis drug Celebrex (celecoxib) was invalid for obviousness-type double patenting.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk